Holen Sie sich die Stockscreener-App
7.895
15.74%
-1.475
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria Bioscience Raises $5.9 Million Via Warrant Exercise; Issues New Warrants, Engages Wainwright - TradingView
Lexaria Raises $5.9 Million Via Warrant Exercise and Issues New Warrants - TipRanks
Lexaria raises $5.9M by exercising warrants at reduced price to fund 2027 operations and R&D. - Pluang
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Investing News Network
Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds - TradingView
A potential $5.9 million plus a $2.6 million rebate may fund Lexaria's 2027 research - Stock Titan
LEXX: Introducing DehydraTECH 3.0 - finance.yahoo.com
Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - Kalkine
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Lexaria to present at H.C. Wainwright Global Investment Conference in September 2026 - Pluang
A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan
Lexaria Bioscience Corp. (LEXX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs - The Globe and Mail
LEXX Looks 131.9% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience advances 12% on Australian tax rebate (LEXX:NASDAQ) - Seeking Alpha
Lexaria enters MTA with PegBio to test GLP-1 delivery tech - scanx.trade
LEXX Looks 129.0% Overvalued on GF Value™ - GuruFocus
Lexaria advances GLP-1 partnerships at BIO 2026 - scanx.trade
Lexaria Bioscience Receives Australian R&D Tax Incentive Credit - TipRanks
LEXX Looks 117.5% Overvalued on GF Value™ - GuruFocus
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com South Africa
Lexaria Bioscience receives AUD$3.67m Australian tax rebate - scanx.trade
Lexaria receives $2.6 million Australian R&D tax rebate - Investing.com
Lexaria nets $2.6M Australian tax rebate to fun... - Pluang
Lexaria Bioscience receives AUD 3.67M Australian R&D tax credit to fund clinical RD - TradingView
Lexaria Receives USD$2.6 Million Tax Rebate Payment - New Castle News
Lexaria DehydraTECH 3.0 Boosts GLP-1 Drug Absorption in 2026 Study - TipRanks
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 - finance.yahoo.com
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Nigeria
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Lexaria Bioscience regains Nasdaq bid-price compliance, listing continued - TradingView
Delisting risk eases as Lexaria (NASDAQ: LEXX) regains bid-price compliance - Stock Titan
Lexaria Bioscience enters MTA with PegBio - TipRanks
LEXX Looks 64.3% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Signs PegBio Deal to Test DehydraTECH With GLP-1 Diabetes Drug - TipRanks
Lexaria Bioscience Corp. Enters Material Transfer Agreement with Pegbio Co., Ltd - marketscreener.com
Lexaria enters partnership with PegBio for GLP-1 drug delivery By Investing.com - Investing.com Australia
Lexaria enters partnership with PegBio for GLP-1 drug delivery - Investing.com
Lexaria Enters a Material Transfer Agreement With PegBio - Investing News Network
Lexaria Enters a Material Transfer Agreement with PegBio - TradingView
Lexaria and PegBio Plan Animal Studies on a GLP-1 Molecule - Stock Titan
Lexaria Bioscience Received Notice of Delisting - TradingView
Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Stock Price Forecast. Should You Buy LEXX? - StockInvest.us
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Stock News Today - TradingKey
Lexaria Provides Update on Human Nicotine Study NIC-H22-1 - TheNewswire
Lexaria Bioscience Corp Authorizes 1-For-15 Reverse Stock SplitSEC Filing - TradingView
Lexaria Bioscience plans 1-for-15 reverse stock split By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp (LEXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexaria Bioscience Corp. Revenue Breakdown – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LEXX|Lexaria Bioscience Corp|Price:0.559|Chg%:-0.011 - TradingKey
Enterprise value to revenue forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Cash Flow - TradingKey
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):